Syed Saleem Abbas Jafri, Muhammad Saleem Akhter, Mumtaz Ahmad, Sajjad Hussain.
Efficacy, Safety and Compliance of Terazosin in the Treatment of patients with Symptomatic Benign Prostatic Hyperplasia
J Ayub Med Coll Abottabad Apr - Jun 2000;12(2):2-6.
Departments of Urology, Jinnah Hospital, Lahore

Background: The primary objective of this study was to determine the efficacy, safety and compliance of terazosin, a selective long-acting alpha 1-blocker, for the treatment of symptomatic BPH. Methods: A total of 150 patients ranging in age between 45 and 81 years with symptomatic BPH were included. They were randomly assigned to receive terazosin (n =74) or placebo (n = 76) for 12 weeks. Results: Terazosin significantly improved urinary symptoms versus placebo, assessed by using the 1-PSS (-30vs. -17%, P=0.007). Maximum flow rate increased significantly with terazosin (2.3 ml/s i.e. + 28%) compared with placebo (1.1 ml/s i.e. +13%, P=0.006). Residual urine was also significantly reduced with terazosin. Overall, terazosin was as well tolerated as placebo. Seven patients were withdrawn from the study for adverse events with terazosin (9.45%) and eight patients (10.52%) with placebo. The incidence of vasodilatationrelated events like postural symptoms, dizziness, headache with terazosin was similar (8.11%) to that of placebo (7.90%). The reduction in supine blood pressure was minor (< 5mm Hg), both in normotensive and hypertensive patients. Conclusion: This study demonstrates the efficacy, safety and compliance of terazosin for the treatment of BPH.

Category: Pharmacology
Keywords: Terazosin. Benign Prostatic Hyperplasia.

Click here for Full Text Article

This article has been viewed 660 times

Submit your Research Synopsis for Free Expert analysis - Search- Feedback - Drug Index
Post and View Comments on this Article